Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Being Investigated on Behalf of bluebird bio, Inc. Investors. Contact Levi & Korsinsky For Details

Accesswire March 14, 2024

BLUE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of bluebird bio, Inc. Shareholders Who Lost Money

Accesswire March 13, 2024

ATTENTION bluebird bio, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

Accesswire March 12, 2024

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Business Wire March 11, 2024

bluebird bio, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BLUE

Accesswire March 11, 2024

Levi & Korsinsky Announces an Investigation on Behalf of bluebird bio, Inc. (BLUE) Shareholders Who May Have Been Affected by Fraud

Accesswire March 8, 2024

Lost Money on bluebird bio, Inc. (BLUE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Accesswire March 7, 2024

Lost Money on bluebird bio, Inc.(BLUE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

Accesswire March 6, 2024

bluebird bio, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BLUE

Accesswire March 5, 2024

Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations

Accesswire March 4, 2024

Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BLUE

Accesswire February 28, 2024

Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BLUE

Accesswire February 26, 2024

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

Business Wire January 8, 2024

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2024

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Business Wire December 19, 2023

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Business Wire December 18, 2023

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Business Wire December 10, 2023

Long-term Follow-up Data From bluebird's Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

Business Wire December 9, 2023

bluebird bio Details Plans for the Commercial Launch of LYFGENIA(TM) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Business Wire December 8, 2023

bluebird bio Announces FDA Approval of LYFGENIA(TM) (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Business Wire December 8, 2023